FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
强生(US:JNJ) Prnewswire·2025-11-06 20:30Accessibility StatementSkip Navigation CAPLYTA, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications In pivotal trials, CAPLYTA did not increase mean weight gain, metabolic changes, or reported sexual side effects Experience the full interactive Multichannel News Release here: https://www.multivu.com/johnson-and- johnson/9355651-en-johnson-and-johnson-fda-approval-caplyta-lumateperone MDD, or clini ...